Price Action Don’t Lie: Walgreens Boots Alliance Inc Rises A lot Today, Is Now One of The Best Performer

Price Action Don't Lie: Walgreens Boots Alliance Inc Rises A lot Today, Is Now One of The Best Performer

The stock of Walgreens Boots Alliance Inc (NASDAQ:WBA) is a huge mover today! About 1.26M shares traded hands. Walgreens Boots Alliance Inc (NASDAQ:WBA) has risen 0.04% since March 1, 2016 and is uptrending. It has underperformed by 9.21% the S&P500.
The move comes after 8 months positive chart setup for the $86.76B company. It was reported on Oct, 4 by Barchart.com. We have $121.40 PT which if reached, will make NASDAQ:WBA worth $44.25 billion more.

Analysts await Walgreens Boots Alliance Inc (NASDAQ:WBA) to report earnings on October, 26. They expect $0.99 earnings per share, up 12.50% or $0.11 from last year’s $0.88 per share. WBA’s profit will be $1.07 billion for 20.30 P/E if the $0.99 EPS becomes a reality. After $1.18 actual earnings per share reported by Walgreens Boots Alliance Inc for the previous quarter, Wall Street now forecasts -16.10% negative EPS growth.

Walgreens Boots Alliance Inc (NASDAQ:WBA) Ratings Coverage

Out of 9 analysts covering Walgreens Boots Alliance (NASDAQ:WBA), 6 rate it a “Buy”, 1 “Sell”, while 2 “Hold”. This means 67% are positive. Walgreens Boots Alliance has been the topic of 17 analyst reports since August 24, 2015 according to StockzIntelligence Inc. The rating was maintained by Credit Suisse on Monday, November 16 with “Outperform”. Credit Suisse maintained Walgreens Boots Alliance Inc (NASDAQ:WBA) rating on Thursday, September 1. Credit Suisse has “Outperform” rating and $95 price target. On Wednesday, September 9 the stock rating was upgraded by Cowen & Co to “Outperform”. The rating was reinitiated by Barclays Capital with “Equal-Weight” on Thursday, March 10. The company was maintained on Tuesday, June 7 by Bank of America. The firm has “Buy” rating by Zacks given on Monday, August 24. The stock of Walgreens Boots Alliance Inc (NASDAQ:WBA) has “Hold” rating given on Tuesday, September 1 by Zacks. On Wednesday, October 28 the stock rating was upgraded by RBC Capital Markets to “Buy”. The rating was maintained by S&P Research on Thursday, October 29 with “Buy”. Credit Suisse maintained Walgreens Boots Alliance Inc (NASDAQ:WBA) rating on Monday, July 18. Credit Suisse has “Outperform” rating and $82.51 price target.

According to Zacks Investment Research, “Walgreens Boots Alliance, Inc. operates as a retail drugstore chain. The Company sells prescription and non-prescription drugs, as well as general merchandise products, including household items, convenience and fresh foods, personal care, beauty care, photofinishing and candy. Its pharmacy, health and wellness services include retail, specialty, infusion and respiratory services, mail service and convenient care clinics. The Company offers its products and services through drugstores, as well as through mail, by telephone and online. Walgreens Boots Alliance, Inc., is based in Deerfield, Illinois.”

WBA Company Profile

Walgreens Boots Alliance, Inc., incorporated on October 2, 2014, is a holding company. The Firm is a pharmacy-led health and wellbeing company. The Firm operates through three divisions: Retail Pharmacy USA, Retail Pharmacy International and Pharmaceutical Wholesale. The Retail Pharmacy USA segment consists of the Walgreen Co. (Walgreens) business, which includes the operation of retail drugstores and convenient care clinics, in addition to providing specialty pharmacy services. The Retail Pharmacy International segment consists primarily of the Alliance Boots pharmacy-led health and beauty stores, optical practices and related contract manufacturing operations. The Pharmaceutical Wholesale segment consists of the Alliance Boots pharmaceutical wholesaling and distribution businesses. The Company’s portfolio of retail and business brands includes Walgreens, Duane Reade, Boots and Alliance Healthcare, as well as global health and beauty product brands, including No7, Botanics, Liz Earle and Soap & Glory.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment